Loading…
Surgical therapy for metastatic disease to the liver
The liver is a common site of hematogenous metastasis. In the past, patients with liver metastases were often deemed inoperable, and medical therapy conferred only minor survival benefit. However, advances in surgical techniques and chemotherapeutic agents during the past two decades have led to eff...
Saved in:
| Published in: | Annual review of medicine 2005-01, Vol.56 (1), p.139-156 |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-a472t-c2e3158399aa41c63e961ced9cea854edf1252eab298afbb6a30fd586ed4e8323 |
|---|---|
| cites | cdi_FETCH-LOGICAL-a472t-c2e3158399aa41c63e961ced9cea854edf1252eab298afbb6a30fd586ed4e8323 |
| container_end_page | 156 |
| container_issue | 1 |
| container_start_page | 139 |
| container_title | Annual review of medicine |
| container_volume | 56 |
| creator | Bentrem, David J Dematteo, Ronald P Blumgart, Leslie H |
| description | The liver is a common site of hematogenous metastasis. In the past, patients with liver metastases were often deemed inoperable, and medical therapy conferred only minor survival benefit. However, advances in surgical techniques and chemotherapeutic agents during the past two decades have led to effective treatments for selected patients with metastases to the liver. Up to approximately 80% of the liver can be resected, and partial hepatectomy is now routinely performed with a perioperative mortality rate of |
| doi_str_mv | 10.1146/annurev.med.56.082103.104630 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67355291</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>817456981</sourcerecordid><originalsourceid>FETCH-LOGICAL-a472t-c2e3158399aa41c63e961ced9cea854edf1252eab298afbb6a30fd586ed4e8323</originalsourceid><addsrcrecordid>eNpdkEtLw0AUhQdRbK3-BQki7hLn3Qy4keILCi5UcDfcTG40JY86kxT6701JcOHqbL5z7-Ej5JrRhDGpb6Fpeo-7pMY8UTqhKWdUJIxKLegRmTMlVSy4_jwmc0q1jiVnZkbOQthQSo0Q6SmZMaU1VVTPiXzr_VfpoIq6b_Sw3UdF66MaOwgddKWL8jIgBIy69kBEVblDf05OCqgCXky5IB-PD--r53j9-vSyul_HIJe8ix1HwVQqjAGQzGmBRjOHuXEIqZKYF4wrjpBxk0KRZRoELXKVaswlpoKLBbkZ7259-9Nj6GxdBodVBQ22fbB6KZTihg3g1T9w0_a-GbZZzrkWZinlAN2NkPNtCB4Lu_VlDX5vGbUHtXZSawe1Vmk7qrWj2qF-Of3oswPwV55cil_cGnhL</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>222639744</pqid></control><display><type>article</type><title>Surgical therapy for metastatic disease to the liver</title><source>Annual Reviews</source><source>Electronic Back Volume Collection (EBVC)</source><creator>Bentrem, David J ; Dematteo, Ronald P ; Blumgart, Leslie H</creator><creatorcontrib>Bentrem, David J ; Dematteo, Ronald P ; Blumgart, Leslie H</creatorcontrib><description>The liver is a common site of hematogenous metastasis. In the past, patients with liver metastases were often deemed inoperable, and medical therapy conferred only minor survival benefit. However, advances in surgical techniques and chemotherapeutic agents during the past two decades have led to effective treatments for selected patients with metastases to the liver. Up to approximately 80% of the liver can be resected, and partial hepatectomy is now routinely performed with a perioperative mortality rate of <5%. Surgical resection of colorectal cancer metastatic to the liver results in a 5-year survival rate of 40%. These results are expected to improve even further with multimodality approaches that include newer chemotherapy regimens. Liver metastases from other primary tumors, such as neuroendocrine carcinoma and genitourinary tumors, are also treated effectively with liver resection. The indications for surgical treatment of liver metastases are broadening as a variety of novel therapies are being developed, including hepatic artery embolization, hepatic artery infusion of chemotherapy, and radiofrequency ablation.</description><identifier>ISSN: 0066-4219</identifier><identifier>EISSN: 1545-326X</identifier><identifier>DOI: 10.1146/annurev.med.56.082103.104630</identifier><identifier>PMID: 15660506</identifier><language>eng</language><publisher>United States: Annual Reviews, Inc</publisher><subject>Carcinoma, Neuroendocrine - drug therapy ; Carcinoma, Neuroendocrine - mortality ; Carcinoma, Neuroendocrine - surgery ; Chemotherapy ; Chemotherapy, Adjuvant ; Colorectal cancer ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - mortality ; Colorectal Neoplasms - surgery ; Combined Modality Therapy ; Feasibility Studies ; Hepatectomy ; Hepatitis ; Humans ; Liver ; Liver Neoplasms - drug therapy ; Liver Neoplasms - mortality ; Liver Neoplasms - secondary ; Liver Neoplasms - surgery ; Surgery ; Survival Rate ; Urogenital Neoplasms - drug therapy ; Urogenital Neoplasms - mortality ; Urogenital Neoplasms - surgery</subject><ispartof>Annual review of medicine, 2005-01, Vol.56 (1), p.139-156</ispartof><rights>Copyright Annual Reviews, Inc. 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a472t-c2e3158399aa41c63e961ced9cea854edf1252eab298afbb6a30fd586ed4e8323</citedby><cites>FETCH-LOGICAL-a472t-c2e3158399aa41c63e961ced9cea854edf1252eab298afbb6a30fd586ed4e8323</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4182,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15660506$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bentrem, David J</creatorcontrib><creatorcontrib>Dematteo, Ronald P</creatorcontrib><creatorcontrib>Blumgart, Leslie H</creatorcontrib><title>Surgical therapy for metastatic disease to the liver</title><title>Annual review of medicine</title><addtitle>Annu Rev Med</addtitle><description>The liver is a common site of hematogenous metastasis. In the past, patients with liver metastases were often deemed inoperable, and medical therapy conferred only minor survival benefit. However, advances in surgical techniques and chemotherapeutic agents during the past two decades have led to effective treatments for selected patients with metastases to the liver. Up to approximately 80% of the liver can be resected, and partial hepatectomy is now routinely performed with a perioperative mortality rate of <5%. Surgical resection of colorectal cancer metastatic to the liver results in a 5-year survival rate of 40%. These results are expected to improve even further with multimodality approaches that include newer chemotherapy regimens. Liver metastases from other primary tumors, such as neuroendocrine carcinoma and genitourinary tumors, are also treated effectively with liver resection. The indications for surgical treatment of liver metastases are broadening as a variety of novel therapies are being developed, including hepatic artery embolization, hepatic artery infusion of chemotherapy, and radiofrequency ablation.</description><subject>Carcinoma, Neuroendocrine - drug therapy</subject><subject>Carcinoma, Neuroendocrine - mortality</subject><subject>Carcinoma, Neuroendocrine - surgery</subject><subject>Chemotherapy</subject><subject>Chemotherapy, Adjuvant</subject><subject>Colorectal cancer</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Colorectal Neoplasms - mortality</subject><subject>Colorectal Neoplasms - surgery</subject><subject>Combined Modality Therapy</subject><subject>Feasibility Studies</subject><subject>Hepatectomy</subject><subject>Hepatitis</subject><subject>Humans</subject><subject>Liver</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - mortality</subject><subject>Liver Neoplasms - secondary</subject><subject>Liver Neoplasms - surgery</subject><subject>Surgery</subject><subject>Survival Rate</subject><subject>Urogenital Neoplasms - drug therapy</subject><subject>Urogenital Neoplasms - mortality</subject><subject>Urogenital Neoplasms - surgery</subject><issn>0066-4219</issn><issn>1545-326X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><recordid>eNpdkEtLw0AUhQdRbK3-BQki7hLn3Qy4keILCi5UcDfcTG40JY86kxT6701JcOHqbL5z7-Ej5JrRhDGpb6Fpeo-7pMY8UTqhKWdUJIxKLegRmTMlVSy4_jwmc0q1jiVnZkbOQthQSo0Q6SmZMaU1VVTPiXzr_VfpoIq6b_Sw3UdF66MaOwgddKWL8jIgBIy69kBEVblDf05OCqgCXky5IB-PD--r53j9-vSyul_HIJe8ix1HwVQqjAGQzGmBRjOHuXEIqZKYF4wrjpBxk0KRZRoELXKVaswlpoKLBbkZ7259-9Nj6GxdBodVBQ22fbB6KZTihg3g1T9w0_a-GbZZzrkWZinlAN2NkPNtCB4Lu_VlDX5vGbUHtXZSawe1Vmk7qrWj2qF-Of3oswPwV55cil_cGnhL</recordid><startdate>20050101</startdate><enddate>20050101</enddate><creator>Bentrem, David J</creator><creator>Dematteo, Ronald P</creator><creator>Blumgart, Leslie H</creator><general>Annual Reviews, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7T5</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>MBDVC</scope><scope>P64</scope><scope>PADUT</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20050101</creationdate><title>Surgical therapy for metastatic disease to the liver</title><author>Bentrem, David J ; Dematteo, Ronald P ; Blumgart, Leslie H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a472t-c2e3158399aa41c63e961ced9cea854edf1252eab298afbb6a30fd586ed4e8323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Carcinoma, Neuroendocrine - drug therapy</topic><topic>Carcinoma, Neuroendocrine - mortality</topic><topic>Carcinoma, Neuroendocrine - surgery</topic><topic>Chemotherapy</topic><topic>Chemotherapy, Adjuvant</topic><topic>Colorectal cancer</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Colorectal Neoplasms - mortality</topic><topic>Colorectal Neoplasms - surgery</topic><topic>Combined Modality Therapy</topic><topic>Feasibility Studies</topic><topic>Hepatectomy</topic><topic>Hepatitis</topic><topic>Humans</topic><topic>Liver</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - mortality</topic><topic>Liver Neoplasms - secondary</topic><topic>Liver Neoplasms - surgery</topic><topic>Surgery</topic><topic>Survival Rate</topic><topic>Urogenital Neoplasms - drug therapy</topic><topic>Urogenital Neoplasms - mortality</topic><topic>Urogenital Neoplasms - surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bentrem, David J</creatorcontrib><creatorcontrib>Dematteo, Ronald P</creatorcontrib><creatorcontrib>Blumgart, Leslie H</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Psychology Database</collection><collection>ProQuest Research Library</collection><collection>ProQuest Science Journals</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Research Library China</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Annual review of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bentrem, David J</au><au>Dematteo, Ronald P</au><au>Blumgart, Leslie H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Surgical therapy for metastatic disease to the liver</atitle><jtitle>Annual review of medicine</jtitle><addtitle>Annu Rev Med</addtitle><date>2005-01-01</date><risdate>2005</risdate><volume>56</volume><issue>1</issue><spage>139</spage><epage>156</epage><pages>139-156</pages><issn>0066-4219</issn><eissn>1545-326X</eissn><abstract>The liver is a common site of hematogenous metastasis. In the past, patients with liver metastases were often deemed inoperable, and medical therapy conferred only minor survival benefit. However, advances in surgical techniques and chemotherapeutic agents during the past two decades have led to effective treatments for selected patients with metastases to the liver. Up to approximately 80% of the liver can be resected, and partial hepatectomy is now routinely performed with a perioperative mortality rate of <5%. Surgical resection of colorectal cancer metastatic to the liver results in a 5-year survival rate of 40%. These results are expected to improve even further with multimodality approaches that include newer chemotherapy regimens. Liver metastases from other primary tumors, such as neuroendocrine carcinoma and genitourinary tumors, are also treated effectively with liver resection. The indications for surgical treatment of liver metastases are broadening as a variety of novel therapies are being developed, including hepatic artery embolization, hepatic artery infusion of chemotherapy, and radiofrequency ablation.</abstract><cop>United States</cop><pub>Annual Reviews, Inc</pub><pmid>15660506</pmid><doi>10.1146/annurev.med.56.082103.104630</doi><tpages>18</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0066-4219 |
| ispartof | Annual review of medicine, 2005-01, Vol.56 (1), p.139-156 |
| issn | 0066-4219 1545-326X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67355291 |
| source | Annual Reviews; Electronic Back Volume Collection (EBVC) |
| subjects | Carcinoma, Neuroendocrine - drug therapy Carcinoma, Neuroendocrine - mortality Carcinoma, Neuroendocrine - surgery Chemotherapy Chemotherapy, Adjuvant Colorectal cancer Colorectal Neoplasms - drug therapy Colorectal Neoplasms - mortality Colorectal Neoplasms - surgery Combined Modality Therapy Feasibility Studies Hepatectomy Hepatitis Humans Liver Liver Neoplasms - drug therapy Liver Neoplasms - mortality Liver Neoplasms - secondary Liver Neoplasms - surgery Surgery Survival Rate Urogenital Neoplasms - drug therapy Urogenital Neoplasms - mortality Urogenital Neoplasms - surgery |
| title | Surgical therapy for metastatic disease to the liver |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T17%3A48%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Surgical%20therapy%20for%20metastatic%20disease%20to%20the%20liver&rft.jtitle=Annual%20review%20of%20medicine&rft.au=Bentrem,%20David%20J&rft.date=2005-01-01&rft.volume=56&rft.issue=1&rft.spage=139&rft.epage=156&rft.pages=139-156&rft.issn=0066-4219&rft.eissn=1545-326X&rft_id=info:doi/10.1146/annurev.med.56.082103.104630&rft_dat=%3Cproquest_cross%3E817456981%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a472t-c2e3158399aa41c63e961ced9cea854edf1252eab298afbb6a30fd586ed4e8323%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=222639744&rft_id=info:pmid/15660506&rfr_iscdi=true |